Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 16/20 | 0.51 |
| ▸ | BRD4 | O60885 | 10/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | CLK2 | P49760 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | NEK4 | P51957 | 1/20 | 0.44 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.44 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.44 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.44 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544473 | 0.89 | PLK1 (0.59) | MAPK7PLK1BRD4BRDTPLK3 | |
| SCHEMBL3539402 | 0.88 | PLK1 (0.58) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3537776 | 0.88 | PLK1 (0.53) | MAPK7PLK1BRD4BRDTIGF1R | |
| SCHEMBL12880142 | 0.86 | PTK2 (0.58) | MAPK7PLK1BRD4BRDTPLK3 | |
| SCHEMBL3541787 | 0.84 | PLK1 (0.53) | MAPK7PLK1BRD4BRDTIGF1R | |
| SCHEMBL25031476 | 0.84 | PLK1 (0.54) | MAPK7PLK1BRD4BRDTPLK3 | |
| SCHEMBL3544894 | 0.83 | PLK1 (0.60) | MAPK7PLK1BRD4BRDTPLK3 | |
| SCHEMBL1560256 | 0.82 | PLK1 (0.70) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3539045 | 0.81 | MAPK7 (0.65) | MAPK7PLK1BRD4BRDTIGF1R | |
| SCHEMBL12880122 | 0.81 | PLK1 (0.71) | MAPK7PLK1BRD4BRDTPLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | MAPK7 1238/4885PLK1 847/4885BRD4 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.